Discover why Lyell Immunopharma (LYEL) stock is up 191% YTD. Explore CAR T therapy breakthroughs, trial milestones, and key investment insights.
At 337.06, the stock's Price to Earnings ratio significantly exceeds the industry average by 19.01x, suggesting a premium ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback